Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | POLG | P54098 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68614 | 1.00 | POLB (0.49) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL14512782 | 1.00 | POLB (0.49) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL16587688 | 0.91 | POLB (0.48) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL16359951 | 0.89 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL12360856 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL23200453 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL27267680 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10432426 | 0.89 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10431788 | 0.89 | LMNA (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL66763 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1783216-A1 | TELOMERASE-INHIBITORY ENA OLIGONUCLEOTIDE | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | POLB 394/4885LMNA 603/4885PDE3A 2565/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | POLB 11/4885LMNA 1087/4885PDE3A 4641/4885 |
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | POLB 17/4885LMNA 950/4885PDE3A 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.